Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.78 |
| ▸ | CTSL | P07711 | 7/20 | 0.78 |
| ▸ | CTSB | P07858 | 5/20 | 0.78 |
| ▸ | CTSS | P25774 | 5/20 | 0.78 |
| ▸ | CTSV | O60911 | 1/20 | 0.73 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841794 | 1.00 | CTSK (0.78) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL28472588 | 1.00 | CTSK (0.78) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL4672231 | 0.94 | CTSK (0.78) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL5742250 | 0.90 | CTSK (0.85) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL11981331 | 0.90 | CTSK (0.75) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL4992553 | 0.88 | CTSK (0.82) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL2155588 | 0.88 | CTSK (0.82) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL8438799 | 0.88 | CTSK (0.61) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL2156489 | 0.88 | CTSK (0.82) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL28457932 | 0.88 | CTSL (0.83) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106866502-B | Cathepsin K inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2020025748-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INTERNATIONAL B.V. (NL) | 2020-02-06 | — | — | WO | disclosed |
| WO-2016095879-A1 | PREPARATION OF A HIGHLY PURE INTERMEDIATE FOR THE SYNTHESIS OF ODANACATIB | ZENTIVA, K.S. (CZ) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016095879-A1 | PREPARATION OF A HIGHLY PURE INTERMEDIATE FOR THE SYNTHESIS OF ODANACATIB | ZENTIVA, K.S. (CZ) | 2016-06-23 | — | — | WO | disclosed |
| US-8791162-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-29 | — | — | US | disclosed |
| US-7407959-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-08-05 | — | — | US | disclosed |
| US-7407959-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-08-05 | — | — | US | disclosed |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | GAUTHIER JACQUES Y | 2007-12-20 | — | — | US | disclosed |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | GAUTHIER JACQUES Y | 2007-12-20 | — | — | US | disclosed |
| EP-1817276-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056047-A9 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006056047-A9 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-06-21 | — | — | WO | disclosed |
| EP-1694647-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006056047-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
| WO-2005056529-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSK 4/4885CTSL 8/4885CTSB 1/4885 |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | CTSB, CTSS, CTSE | CTSK 7/4885CTSL 10/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.